<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Familial amyloidotic <z:hpo ids='HP_0001271'>polyneuropathy</z:hpo> (FAP) is a protein folding disorder that induces <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> and <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo>, leading to <z:hpo ids='HP_0011420'>death</z:hpo> within 7-15 years after <z:hpo ids='HP_0003674'>onset</z:hpo> of clinical disease </plain></SENT>
<SENT sid="1" pm="."><plain>In vitro, small ligands binding the thyroid hormone docking site stabilize tetrameric transthyretin, inhibiting amyloid fibril formation </plain></SENT>
<SENT sid="2" pm="."><plain>We undertook a randomized, placebo-controlled clinical trial to determine whether <z:chebi fb="0" ids="39669">diflunisal</z:chebi>, a well-known <z:chebi fb="2" ids="35475">non-steroidal anti-inflammatory drug</z:chebi> (<z:chebi fb="1" ids="35475">NSAID</z:chebi>) alters neurologic disease progression in FAP </plain></SENT>
<SENT sid="3" pm="."><plain>We enrolled 130 subjects with wide age and FAP mutation representation </plain></SENT>
<SENT sid="4" pm="."><plain>To date, few recognized complications of <z:chebi fb="1" ids="35475">NSAIDs</z:chebi> have occurred in the study cohort </plain></SENT>
<SENT sid="5" pm="."><plain>Data collection will be completed by November 2012 </plain></SENT>
</text></document>